期刊文献+

非小细胞肺癌组织中P53和C-erbB-2蛋白的表达 被引量:2

Expression of P53 and C-erbB-2 in non-small cell lung cancer tissue
下载PDF
导出
摘要 目的:检测非小细胞肺癌(NSCLC)组织中P53和C-erbB-2蛋白的表达。方法:采用免疫组织化学SP法检测30例癌旁正常组织和58例NSCLC组织中P53和C-erbB-2的表达,结合临床资料进行分析。结果:NSCLC组织中P53和C-erbB-2蛋白的阳性表达率分别为63.8%(37/58)和70.7%(41/58),均高于癌旁正常组织(13.3%(4/30),17.7%(5/30),P均<0.05)。NSCLC淋巴结转移组P53和C-erbB-2蛋白的阳性表达率分别为75.0%和80.0%,均高于无淋巴结转移组(38.9%,50.0%,P均<0.05)。NSCLC组织中P53和C-erbB-2的表达有关(χ2=5.32,P<0.05)。结论:NSCLC组织中P53和C-erbB-2蛋白高表达,2者可能共同参与了NSCLC的发生发展与转移。 Aim: To investigate the expression of P53 and C-erbB-2 in non-small cell lung cancer(NSCLC) tissue. Methods:The expressions of P53 and C-erbB-2 in 30 eases of normal tissue by the side of cancer and 58 eases of NSCLC tissue were detected by S-P immunohistoehemistry. Results:The positive expression rates of P53 and C-erbB-2 protein in NSCLC tissue were 63.8% and 70.7% , significantly higher than those in normal tissue ( 13.3 % , 17.7% ,P 〈 0.05 ) , re- spectively. In NSCLC tissue, the positive expression rates of P53 and C-erbB-2 protein in lymph node metastasis group were higher than those in the group without lymph node metastasis ( P 〈0.05 ). The positive expression of P53 in NSCLC tissue was related with that of C-erbB-2. Conclusion :P53 and C-erbB-2 in NSCLC tissue are highly expressed and they may in- volve in the development and lymph node metastasis of NSCLC.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2008年第5期976-978,共3页 Journal of Zhengzhou University(Medical Sciences)
关键词 非小细胞肺癌 P53 C—erbB-2 淋巴结转移 non-small cell lung cancer P53 C-erbB-2 lymph node metastasis
  • 相关文献

参考文献6

二级参考文献39

  • 1张丽华,侯振江.p53基因在肺癌研究中的进展[J].临床肺科杂志,2006,11(1):59-60. 被引量:18
  • 2AMBROSINI G,ADIDA C,ALTIERI D C.A novel anti-apoptosis gene,survivin,expressed in cancer and lymphoma[J].Nat Med,1997,3(8):917-921.
  • 3REKER S,BECKER J C,SVANE I M,et al.HLA-B35-restricted immune responses against survivin in cancer patients[J].Int J Cancer,2004,108(6):937 -941.
  • 4SUZUKI A,ITO T,KAWANO H,et al.Survivin initiates procaspase 3/p21 complex formation as a result of interaction with CDK4 to resist Fas-mediated cell death[J].Oncogene,2000,19 (10):1346 -1353.
  • 5KARCZMAREK-BOROWSKA B,FILIP A,WOJCIEROWSKI J,et al.Survivin antiapoptotic gene expression as a prognostic factor in nonsmall cell lung cancer:in situ hybridization study[J].Folia Histochem Cytobiol,2005,43 (4):237-242.
  • 6MONZO M,ROSELL R,FELIP E,et al.A novel anti-apoptosis gene:Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers[J].J Clin Oncol,1999,17(7):2100-2104.
  • 7SARELA A I,MACADAM R C,FARMERY S M,et al.Expression of the antiapoptosis gene,survivin,predicts death from recurrent colorectal carcinoma[J].Gut,2000,46(5):645 -650.
  • 8MESRI M,WALL N R,LI J,et al.Cancer gene therapy using a survivin mutant adenovirus[J].J Clin Invest,2001,108 (7):981-990.
  • 9TUTOR O,DIAZ M A,RAMIREZ M,et al.Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia[J].Leuk Res,2002,26(9):817 -820.
  • 10TOKUGAWA T,SUGIHARA H,TANI T,et al.Modes of silencing of p16 in development of esophageal squamous cell carcinoma[J].Cancer Res,2002,62(17):4938-4944.

共引文献24

同被引文献12

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部